SpinTech MRI Earns FDA Clearance for Rapid, Quantitative Brain-Imaging Technology
STAGE, developed by SpinTech, Inc., reduces time to capture complete brain scans while providing higher-quality image outputs.
BINGHAM FARMS, Mich., Aug. 10, 2021 /PRNewswire/ -- The US Food and Drug Administration (FDA) has approved SpinTech, Inc.'s latest magnetic resonance imaging software device, STAGE (Strategically Acquired Gradient Echo), a post-processing software platform that enables comprehensive, quantitative brain imaging with enhanced visualization in significantly less time than conventional approaches. STAGE allows MRI technicians to acquire 16 brain imaging contrasts, including 10 enhanced contrast qualitative outputs and 6 quantitative outputs in just 5 minutes on 3T systems. STAGE is cleared for use on both 1.5T and 3T systems across manufacturers, and runs on existing equipment.
"STAGE's FDA clearance is a huge breakthrough for SpinTech," said Ward Detwiler, SpinTech's CEO. "After years of developing and refining the platform through extensive research use, we are incredibly excited to make this game-changing technology available for clinical use in hospitals and imaging centers."
Aside from its enhanced contrast qualitative outputs, STAGE generates quantitative outputs such as T1 & PD maps, and is the first 510(k) cleared product to provide Quantitative Susceptibility Mapping (QSM). Through the company's extensive research partnerships, they have established powerful clinical use cases across numerous diagnostic areas. When interpreted by a trained physician, STAGE-processed images may provide information useful in determining diagnosis for stroke, dementia, Parkinson's, multiple sclerosis, tumors and more.
"Radiologists have long struggled to obtain comprehensive, high-quality clinical data within very constricted scanning windows," said Dr. Mark Haacke, PhD, Founder and Chief Science Officer at SpinTech. "Now, they don't need to choose which sequences to run, just what they are going to examine, as all the data they need has already been collected. On top of the enhanced imaging data, radiology groups will also benefit from increased patient throughput. And, of course, patients experience shorter scan times, so everybody wins."
Hospitals or imaging centers can improve the efficacy of their MR imaging systems, both old and new, without taking machines offline or investing in expensive hardware. STAGE is compatible with nearly any existing MRI, providing standardized image outputs across different manufacturers and enabling more reliable longitudinal comparison across different machines.
"We have seen, pretty consistently, that reimbursement rates are declining while demand for advanced MRI has increased, putting a lot of pressure on imaging groups," said Detwiler. "Technology solutions that improve both cost and workflow efficiency of imaging procedures are paramount to hospitals and imaging centers, and STAGE perfectly fits that bill."
Though STAGE is considered a comprehensive brain imaging post-processing solution, its approval does not extend outside of brain uses and should always be used in combination with at least one other conventional MR acquisition technique. The software is currently in use in over 50 hospitals, imaging centers and research facilities around the globe. In response to growing commercial interest, SpinTech is currently raising additional capital to scale their sales and services and bring a pipeline of future products to market.
About SpinTech
SpinTech produces rapid, quantitative brain imaging software which assists clinicians and researchers in the quick acquisition and interpretation of MRI results. Through enhanced early detection and quantification of biomarkers critical to many neurological disorders, SpinTech technology aids in improving patient outcomes and efficiency, all while reducing costs. Learn more about SpinTech at https://spintechimaging.com
Media Contact:
Erich Boileau
Boileau Communications Management
[email protected]
616.786.4461
SOURCE SpinTech MRI
Share this article